

Johanne Silvain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3305986/publications.pdf>

Version: 2024-02-01

138
papers

9,488
citations

66234

42
h-index

38300

95
g-index

149
all docs

149
docs citations

149
times ranked

8312
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. <i>Lancet, The</i> , 2009, 373, 309-317.	6.3	864
2	Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. <i>New England Journal of Medicine</i> , 2012, 367, 2100-2109.	13.9	788
3	Pretreatment with Prasugrel in Non- σ ST-Segment Elevation Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2013, 369, 999-1010.	13.9	539
4	Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2014, 371, 1016-1027.	13.9	538
5	Acute Myocardial Infarction. <i>Circulation</i> , 2017, 136, 1908-1919.	1.6	352
6	Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration. <i>Journal of the American College of Cardiology</i> , 2010, 56, 134-143.	1.2	348
7	Composition of Coronary Thrombus in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1359-1367.	1.2	329
8	Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. <i>Lancet, The</i> , 2016, 388, 2015-2022.	6.3	303
9	Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. <i>Lancet, The</i> , 2014, 384, 1577-1585.	6.3	269
10	Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. <i>Lancet, The</i> , 2011, 378, 693-703.	6.3	264
11	Immediate vs Delayed Intervention for Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 947.	3.8	255
12	Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients with Non- σ ST-Elevation Acute Coronary Syndrome. <i>Circulation</i> , 2016, 134, 906-917.	1.6	246
13	Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1765-74.	3.8	179
14	Association of Clopidogrel Pretreatment With Mortality, Cardiovascular Events, and Major Bleeding Among Patients Undergoing Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2507.	3.8	175
15	Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021, 385, 297-308.	13.9	172
16	Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2012, 344, e553-e553.	2.4	159
17	Association of the PHACTR1/EDN1 Genetic Locus With Spontaneous Coronary Artery Dissection. <i>Journal of the American College of Cardiology</i> , 2019, 73, 58-66.	1.2	147
18	Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 552.	3.8	137

#	ARTICLE	IF	CITATIONS
19	Periprocedural myocardial infarction and injury in elective coronary stenting. <i>European Heart Journal</i> , 2018, 39, 1100-1109.	1.0	136
20	High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. <i>European Heart Journal</i> , 2012, 33, 1241-1249.	1.0	127
21	Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1676-1685.	1.2	124
22	High Doses of Clopidogrel to Overcome Genetic Resistance. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 392-402.	1.1	118
23	Can We Override Clopidogrel Resistance?. <i>Circulation</i> , 2009, 119, 2854-2857.	1.6	115
24	<i>CYP2C19</i> But Not <i>PON1</i> Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post-Myocardial Infarction Patients. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 422-428.	1.4	110
25	New P2Y12 Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1542-1551.	1.2	104
26	P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2016, 116, 369-378.	1.8	97
27	Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose. <i>Circulation</i> , 2008, 118, 1225-1233.	1.6	87
28	Early Aldosterone Blockade in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1917-1927.	1.2	86
29	Long-Term Evolution of Premature Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1868-1878.	1.2	81
30	Impact of Red Blood Cell Transfusion on Platelet Aggregation and Inflammatory Response in Anemic Coronary and Noncoronary Patients. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1289-1296.	1.2	78
31	Coronavirus Disease 2019 Acute Myocarditis and Multisystem Inflammatory Syndrome in Adult Intensive and Cardiac Care Units. <i>Chest</i> , 2021, 159, 657-662.	0.4	78
32	Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. <i>BMJ</i> , The, 2014, 347, g6269-g6269.	3.0	75
33	Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. <i>Lancet</i> , The, 2020, 396, 1737-1744.	6.3	75
34	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2021, 42, 2630-2642.	1.0	69
35	Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data. <i>European Heart Journal</i> , 2021, 42, 323-334.	1.0	68
36	Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study. <i>European Heart Journal</i> , 2010, 31, 2816-2821.	1.0	62

#	ARTICLE	IF	CITATIONS
37	Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel. JACC: Cardiovascular Interventions, 2013, 6, 158-165.	1.1	60
38	Efficacy of Ex Vivo Autologous and In Vivo Platelet Transfusion in the Reversal of P2Y ₁₂ Inhibition by Clopidogrel, Prasugrel, and Ticagrelor. Circulation: Cardiovascular Interventions, 2015, 8, e002786.	1.4	59
39	Association of Serum Cholesterol Efflux Capacity With Mortality in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2018, 72, 3259-3269.	1.2	55
40	A Direct Comparison of Intravenous Enoxaparin With Unfractionated Heparin in Primary Percutaneous Coronary Intervention (from the ATOLL Trial). American Journal of Cardiology, 2013, 112, 1367-1372.	0.7	54
41	High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Coronary Stent Revascularization. Circulation, 2014, 129, 2136-2143.	1.6	46
42	Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with Low Dose Aspirin: The UGLA survey. International Journal of Cardiology, 2012, 156, 69-75.	0.8	44
43	Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. American Heart Journal, 2013, 165, 515-522.	1.2	43
44	Prasugrel Monitoring and Bleeding in Real World Patients. American Journal of Cardiology, 2013, 111, 38-44.	0.7	41
45	Contrast-induced acute kidney injury and mortality in ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart, 2018, 104, 767-772.	1.2	41
46	Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 225-235.	1.4	40
47	Microparticles and sudden cardiac death due to coronary occlusion. The TIDE (Thrombus and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 28-36.	0.4	39
48	Pretreatment with P2Y ₁₂ Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy. Circulation, 2014, 130, 1904-1914.	1.6	36
49	Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure. Circulation: Cardiovascular Interventions, 2020, 13, e008481.	1.4	35
50	Determinants of improved one-year survival in non-ST-segment elevation myocardial infarction patients: Insights from the French FAST-MI program over 15years. International Journal of Cardiology, 2014, 177, 281-286.	0.8	33
51	Quantitative flow ratio virtual stenting and post stenting correlations to post stenting fractional flow reserve measurements from the DOCTORS (Does Optical Coherence Tomography Optimize Results) Tj ETQq1 d. 0.784334 rgBT /Dv	1.0	34
52	Dual antiplatelet therapy: optimal timing, management, and duration. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 198-204.	1.4	32
53	Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. European Journal of Clinical Pharmacology, 2015, 71, 1315-1324.	0.8	31
54	Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2016, 9, 646-656.	1.1	31

#	ARTICLE	IF	CITATIONS
55	Usefulness of Biomarker Strategy to Improve GRACE Score's Prediction Performance in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome and Low Event Rates. <i>American Journal of Cardiology</i> , 2010, 106, 650-658.	0.7	28
56	Slow Response to Clopidogrel Predicts Low Response. <i>Journal of the American College of Cardiology</i> , 2010, 55, 815-822.	1.2	28
57	Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. <i>International Journal of Cardiology</i> , 2013, 167, 73-79.	0.8	28
58	The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis. <i>EuroIntervention</i> , 2018, 14, 78-85.	1.4	28
59	Ticagrelor in the Renal Dysfunction Subgroup: Subjugated or Substantiated?. <i>Circulation</i> , 2010, 122, 1049-1052.	1.6	27
60	Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 182-190.	0.7	27
61	One-year clinical outcomes of the STENTYS Self-Apposing™ coronary stent in patients presenting with ST-segment elevation myocardial infarction: results from the APPOSITION III registry. <i>EuroIntervention</i> , 2015, 11, 264-271.	1.4	26
62	Platelet reactivity in human immunodeficiency virus-infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVEREST-2/ST-HIV study. <i>European Heart Journal</i> , 2017, 38, ehw583.	1.0	25
63	Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: The randomized AMERICA Study. <i>International Journal of Cardiology</i> , 2018, 254, 36-42.	0.8	25
64	Thrombus composition in sudden cardiac death from acute myocardial infarction. <i>Resuscitation</i> , 2017, 113, 108-114.	1.3	24
65	Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 104-112.	0.7	23
66	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 173-183.	1.0	23
67	Interleukin-1 β and Risk of Premature Death in Patients With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1763-1773.	1.2	23
68	Enoxaparin Anticoagulation Monitoring in the Catheterization Laboratory Using a New Bedside Test. <i>Journal of the American College of Cardiology</i> , 2010, 55, 617-625.	1.2	22
69	2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 324-333.	1.4	22
70	Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. <i>International Journal of Cardiology</i> , 2013, 163, 266-271.	0.8	21
71	Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: Design of the randomized antarctic study. <i>American Heart Journal</i> , 2014, 168, 674-681.e1.	1.2	21
72	Primary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians. <i>Heart</i> , 2016, 102, 1648-1654.	1.2	21

#	ARTICLE	IF	CITATIONS
73	Contrast-induced nephropathy: the sin of primary percutaneous coronary intervention?. <i>European Heart Journal</i> , 2014, 35, 1504-1506.	1.0	20
74	Updates and Current Recommendations for the Management of Patients With Non-“ST-Elevation Acute Coronary Syndromes: What It Means for Clinical Practice. <i>American Journal of Cardiology</i> , 2015, 115, 10A-22A.	0.7	20
75	Coronary Revascularization in the Diabetic Patient. <i>Circulation</i> , 2014, 130, 918-922.	1.6	19
76	Copeptin as a prognostic biomarker in acute myocardial infarction. <i>International Journal of Cardiology</i> , 2019, 274, 337-341.	0.8	19
77	On- Versus Off-Hours Presentation and Mortality of ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2260-2268.	1.1	18
78	Sex-related differences after contemporary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 428-436.	0.7	17
79	FXIII-A Leu34 genetic variant in premature coronary artery disease: A genotype “ phenotype case control study. <i>Thrombosis and Haemostasis</i> , 2011, 106, 511-520.	1.8	16
80	Pharmacogenetics of Clopidogrel. <i>Current Pharmaceutical Design</i> , 2012, 18, 5309-5327.	0.9	16
81	Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach. <i>Drugs and Aging</i> , 2019, 36, 531-539.	1.3	16
82	Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial. <i>American Heart Journal</i> , 2020, 225, 60-68.	1.2	16
83	Do Patients need Lifelong β -Blockers after an Uncomplicated Myocardial Infarction?. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 431-438.	1.0	15
84	One-Year Major Cardiovascular Events After Restrictive Versus Liberal Blood Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Trial. <i>Circulation</i> , 2022, 145, 486-488.	1.6	15
85	Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2016, 115, 382-391.	1.8	14
86	Anticoagulation in Acute Coronary Syndrome-State of the Art. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 508-513.	1.6	14
87	Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-“ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 906-914.	1.2	14
88	Clopidogrel resistance: What's new?. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 349-353.	0.7	13
89	Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 95-103.	1.4	13
90	Impact of transfer time on mortality in acute coronary syndrome with ST-segment elevation treated by angioplasty. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 639-648.	0.7	13

#	ARTICLE	IF	CITATIONS
91	One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent. <i>Archives of Cardiovascular Diseases</i> , 2011, 104, 604-610.	0.7	11
92	Impact of anticoagulation on ionic and nonionic contrast media effect on thrombogenesis and fibrinolysis: The PÉPCIT study. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 823-833.	0.7	11
93	An evidence-based review of current anti-platelet options for STEMI patients. <i>International Journal of Cardiology</i> , 2013, 166, 294-303.	0.8	11
94	Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 554-562.	0.7	11
95	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 065-074.	1.8	11
96	Comparison of bleeding complications and 3-year survival with low-molecular-weight heparin versus unfractionated heparin for acute myocardial infarction: The FAST-MI registry. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 347-354.	0.7	10
97	Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1055-1064.	1.8	10
98	Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention. <i>Angiology</i> , 2017, 68, 29-39.	0.8	10
99	Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as biomarkers of acute kidney injury after ST-segment elevation myocardial infarction treated by percutaneous coronary intervention. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 180-186.	0.7	10
100	Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1049-1057.	0.8	9
101	Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up trial. <i>American Heart Journal</i> , 2015, 170, 778-786.	1.2	9
102	Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 503-511.	1.0	9
103	Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 680.	1.0	9
104	Clinical manifestations and outcomes of coronavirus disease-19 in heart transplant recipients: a multicentre case series with a systematic review and meta-analysis. <i>Transplant International</i> , 2021, 34, 721-731.	0.8	9
105	Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 502-510.	0.7	8
106	Restrictive vs liberal red blood cell transfusion strategies in patients with acute myocardial infarction and anemia: Rationale and design of the REALITY trial. <i>Clinical Cardiology</i> , 2021, 44, 143-150.	0.7	8
107	Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation. <i>Clinical Cardiology</i> , 2016, 39, 192-200.	0.7	7
108	Selatogrel for Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2598-2601.	1.2	7

#	ARTICLE	IF	CITATIONS
109	Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study. <i>American Heart Journal</i> , 2020, 225, 27-37.	1.2	6
110	Investigator Versus Core Laboratory Evaluation of Coronary Flow and Related Mortality in the CULPRIT-SHOCK Trial. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008296.	1.4	5
111	Short-term effects of the smoke-free legislation on haemostasis and systemic inflammation due to second hand smoke exposure. <i>Thrombosis and Haemostasis</i> , 2011, 105, 1024-1031.	1.8	4
112	Rapid P2Y ₁₂ Inhibition. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 328-331.	1.4	4
113	Long-Term Secondary Prevention After High-Risk Stenting. <i>Circulation</i> , 2015, 131, 13-16.	1.6	4
114	Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 43-53.	1.0	4
115	Modulation of cholesterol efflux capacity in patients with myocardial infarction. <i>Current Opinion in Cardiology</i> , 2019, 34, 714-720.	0.8	4
116	Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs. Multivessel PCI in Cardiogenic Shock Trial. <i>Chest</i> , 2021, 159, 1415-1425.	0.4	4
117	Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 681-691.	1.0	4
118	Impact of age on the effect of pre-hospital P2Y ₁₂ receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis. <i>EuroIntervention</i> , 2018, 14, 789-797.	1.4	4
119	One-Year Clinical Outcomes of Patients Presenting With ST-Segment Elevation Myocardial Infarction Caused by Bifurcation Culprit Lesions Treated With the Stentys Self-Apposing Coronary Stent: Results From the APPOSITION III Study. <i>Journal of Invasive Cardiology</i> , 2017, 29, 253-258.	0.4	4
120	Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analyses. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2023, 9, 194-202.	1.8	4
121	Anticoagulant for primary percutaneous coronary intervention – the last dance for unfractionated heparin?. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 259-261.	0.7	3
122	Potent P2Y ₁₂ Inhibitors in Low-Risk Patients. <i>Journal of the American College of Cardiology</i> , 2016, 67, 614-617.	1.2	3
123	New Insights for Low Dosing With the New P2Y ₁₂ Inhibitors. <i>Circulation Journal</i> , 2014, 78, 2840-2842.	0.7	2
124	Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction in Nonagenarians: A Multicenter Study. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 384-386.	1.3	2
125	Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007749.	1.4	2
126	Kidney in the transformation matrix. <i>European Heart Journal</i> , 2019, 40, 1233-1235.	1.0	2

#	ARTICLE	IF	CITATIONS
127	Appropriate criteria for the definition of Type 4a MI. European Heart Journal, 2021, , .	1.0	2
128	Antiplatelet options for secondary prevention in acute coronary syndromes. Expert Review of Cardiovascular Therapy, 2011, 9, 1403-1415.	0.6	1
129	Reply. Journal of the American College of Cardiology, 2014, 63, 2588-2589.	1.2	1
130	Pretreatment with P2Y12 inhibitors in non-â€“ST-segment elevation acute coronary syndrome: Time to revise the guidelines?. Archives of Cardiovascular Diseases, 2014, 107, 1-3.	0.7	1
131	Platelet Function Test-â€“Guided Strategy. Circulation: Cardiovascular Interventions, 2015, 8, e002716.	1.4	1
132	Cangrelor. JACC: Cardiovascular Interventions, 2016, 9, 1914-1916.	1.1	1
133	Premature coronary artery disease. Sang Thrombose Vaisseaux, 2012, 24, 173-182.	0.1	0
134	TCT-138 Clopidogrel Pretreatment in Non ST Elevation Acute Coronary Syndroms: no effect on mortality, decrease in ischemic endpoints at a price of more major bleeding.. Journal of the American College of Cardiology, 2013, 62, B44.	1.2	0
135	Assessment of the Anticoagulation Activity of Apixaban-â€“â€“ Reply -â€“. Circulation Journal, 2015, 79, 1642.	0.7	0
136	EVALUATION OF INTRACORONARY THROMBUS BY OPTICAL COHERENCE TOMOGRAPHY (OCT): CHARACTERIZATION, QUANTIFICATION AND PROGNOSTIC IMPACT IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME - A DOCTORS SUBSTUDY. Journal of the American College of Cardiology, 2018, 71, A1182.	1.2	0
137	Reply. Journal of the American College of Cardiology, 2020, 76, 486-487.	1.2	0
138	Oral Antiplatelet Therapy. , 2010, , 73-82.		0